Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation
Nutrients · 30.05.2026 · 18 (11) · 1765
DOI: 10.3390/nu18111765 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 30.05.2026. Verfasst von Carlo Acierno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, San Carlo Hospital, 85100 Potenza, Italy. Hauptthemen laut MEDLINE: Prebiotics, Fecal Microbiota Transplantation, Probiotics, Gastrointestinal Microbiome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent liver-centred manifestation of systemic metabolic dysfunction. The gut–liver axis provides a biologically credible therapeutic rationale because intestinal dysbiosis, impaired barrier integrity, microbial metabolites, bile acid signalling, short-chain fatty acids, and trimethylamine N-oxide may influence hepatic steatosis, inflammation, and fibrogenesis. This narrative review critically evaluates dietary patterns, prebiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) as microbiome-directed strategies in MASLD. The comparative framework prioritises disease-specific human evidence, clinically meaningful endpoints, trial duration and sample size, reproducibility, safety, and feasibility. Dietary optimisation remains the most clinically grounded intervention, whereas probiotics and synbiotics show modest and heterogeneous signals on biochemical or metabolic surrogate endpoints. Prebiotics are mechanistically coherent but supported by limited liver-centred trials. Postbiotics and microbiome-mediated bioactives remain early-stage and require stricter definitional boundaries. FMT is investigational and should not be extrapolated from its established role in recurrent Clostridioides difficile infection. Most available evidence across all intervention categories relies principally on surrogate endpoints—including aminotransferases, insulin resistance indices, lipid parameters, and microbiome compositional shifts—rather than on validated liver-centred outcomes such as histological improvement or quantitative liver fat assessment; this constrains the strength of conclusions that can currently be drawn. Across all categories, microbiome modulation does not by itself establish liver disease modification, and no microbiome-targeted nutritional intervention has yet demonstrated histological benefit in MASLD. Future trials in this field should prioritise validated hepatic endpoints, phenotype-stratified patient enrolment, adequate follow-up duration, and direct comparisons between intervention categories to determine which microbiome-directed strategies, if any, deliver measurable and reproducible hepatic benefit beyond surrogate markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, San Carlo Hospital, 85100 Potenza, Italy.
- Department of Medicine and Surgery, University of Basilicata, 85100 Potenza, Italy.
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy.
- Department of Anesthesiology and Intensive Care, San Carlo Hospital, 85100 Potenza, Italy.
- Department of Medicine and Health Science "Vincenzo Tiberio", Università Degli Studi del Molise, 86100 Campobasso, Italy.
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
ORCID-Profile: Carlo Acierno, Alfredo Caturano, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Riccardo Nevola
Zitieren
APA
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026). Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation. Nutrients, 18(11), 1765. https://doi.org/10.3390/nu18111765
Vancouver
Acierno C, Caturano A, Barletta F, Rinaldi L, Sasso FC, Adinolfi LE, et al. Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation. Nutrients. 2026;18(11):1765. doi:10.3390/nu18111765
BibTeX
@article{Acierno2026,
author = {Acierno, Carlo and Caturano, Alfredo and Barletta, Fannia and Rinaldi, Luca and Sasso, Ferdinando Carlo and Adinolfi, Luigi Elio and Nevola, Riccardo},
title = {Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {11},
pages = {1765},
doi = {10.3390/nu18111765}
}
EUVIMED